Listing 1 - 10 of 78 | << page >> |
Sort by
|
Choose an application
For centuries, humans have tried to explain the complex process of vision and find effective treatments for eye diseases. Perhaps the oldest surviving record of ancient ophthalmic practices is the Babylonian code of Hammurabi that over 4000 years ago, mentioned fees for eye surgery and penalties for unsuccessful operations that led to loss of the eye. Babylonian medicine was controlled by priests who directed the work of skilled surgeons. The earliest records of Egyptian medicine date from almost the same time. The Ebers Papyrus, dating back to more than 3500 years ago is a superbly preserved document in which a section outlines a relatively advanced system of diagnosis and treatment of various ocular pathologies. The text reveals that ancient Greek and Egyptian physicians prescribed liver juice for night blindness. This was obtained from roasted and crushed ox liver. We now know that their prescription contained a remarkable amount of vitamin A. It was only within the last century, however, that we have recognized the importance of vitamin A to the function of photoreceptors and visual acuity and that its deficiency can result in night blindness. Egyptian ophthalmological practices were held in high esteem in the ancient world and so were their medical institutes, called peri-ankh, which existed since the first dynasty. Herodotus, the fifth century BC Greek historian, comments on the specialization of the physicians: Each physician treats just one disease.
Choose an application
Choose an application
Choose an application
Choose an application
Choose an application
Eye --- Retinal degeneration --- Aging
Choose an application
Retinal Degeneration --- Cysts --- pathology
Choose an application
Choose an application
Age-related macular degeneration (AMD) is the most common form of macular degeneration and is the term given to ageing changes in the eye without any other obvious cause. These changes occur in the central area of the retina (macula). It is a painless eye condition that generally leads to the gradual impairment of vision, but can sometimes cause a rapid reduction in vision. AMD may be an incidental finding on a routine visit to the optometrist or people may present with difficulty in performing daily activities such as driving, reading and recognising faces. This guideline provides advice on the management of people with AMD, including pharmacological and non-pharmacological treatments. It also provides guidance on tools available to diagnose and monitor AMD, and what information and support should be provided for people with AMD.
Choose an application
Age-related macular degeneration (AMD) is the leading cause of blindness among white Americans and others of European descent, with lower prevalence among those of Asian, Latino, or African ancestry. The overall prevalence of AMD is approximately 8.7 percent worldwide and is expected to rise to 196 million people worldwide by 2020 and 288 million by 2040. AMD typically affects people age 50 and older, and the prevalence increases with age, particularly after the age of 75. In November 2014 the Institute of Medicine's Forum on Neuroscience and Nervous System Disorders hosted a workshop to discuss opportunities for advancing drug development for dry AMD. This report summarizes the presentation and discussion of that workshop.
Listing 1 - 10 of 78 | << page >> |
Sort by
|